The Relationship among Pore-Size Ratings, Bubble Points, and Porosity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relationship among Pore-Size Ratings, Bubble Points, and Porosity


Pharmaceutical Technology


35. EMEA CPMP/QMP/489/95, Note For Guidance in Manufacture of the Finished Dosage Form, 5-6 (April reissue 1996).

36. J.P. Agalloco, "Guest Editorial: It Just Doesn't Matter," PDA J. Pharm. Sci. Technol. 52 (4), 149–150 (1998).

37. Society of Automotive Engineers (SAE), Bubble Point Test. Method, Aerospace Recommended Practice ARP-901 (1968).

38. M.W. Jornitz and T.H. Meltzer, Filtration Handbook: Integrity Testing (PDA, Bethesda, MD; DHI Publishing, River Grove, IL, 2003).

39. D.B. Pall, "Quality Control of Absolute Bacteria Removal Filters," Bull. PDA 29, 192–212 (1975).

40. A. Baszkin, D.J. Lyman, and T.H. Meltzer, "Theoretical Considerations of BubblePoint Measurement: Solid/Liquid Wetting Interaction," Pharm. Technol. Int. 2 (l), 22–31 (1978).

41. P.R. Johnston and T.H. Meltzer, "Comments on Organism Challenge Levels in Sterilizing-Filter Efficiency Testing," Pharm. Technol. 3 (11), 66–70, 110 (1979).

42. W.J. Elford, "The Principles of Ultrafiltration as Applied in Biological Studies," Proceedings of the Royal Society, 112B (London, UK, 1933), pp. 384–406.

43. A.R. Reti, "An Assessment of Test Criteria in Evaluating the Performance and Integrity of Sterilizing Filters," Bull. Paren Drug Assoc. 3l (4), 187–194 (1977).

44. D.C. Grant and J.G. Zahke, "Sieving Capture of Particles by MicroporousMembrane Filters From Clean Liquids," Swiss Contamin. Control 3 (4a), 160–164 (1990).

45. M.L. Roberts and D.J. Valazquez, "Characterizing the Rating and Performance of Membrane Filter for Liquid Applications Using Latex Spheres," Swiss Contam. Quarterly 3, 71–74 (1990).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here